Rhythm Pharmaceuticals, Inc. (RYTM): Cash & Equivalents
$54.30M
As of 2025-12-31
$65.61M
As of 2026-06-30
-24.8%
3-year compound annual growth
-11.6%
5-year compound annual growth
+4.5%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $54.30M | -39.1% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $89.14M | +48.4% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $60.08M | -52.9% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $127.68M | +115.5% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $59.25M | -41.3% | 2023-03-01, Balance as of period end |
| 2020-12-31 | $100.85M | +61.9% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $62.29M | +25.7% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $49.54M | +44.7% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $34.24M | +423.5% | 2019-03-08, Balance as of period end |
| 2016-12-31 | $6.54M | -81.2% | 2018-03-12, Balance as of period end |
| 2015-12-31 | $34.87M | n/a | 2018-03-12, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $54.30M | -39.1% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $216.89M | -32.7% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $84.22M | -34.2% |
| Lifevantage Corp (LFVN) | 2025-06-30 | $20.20M | +19.6% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $250.49M | +633.8% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $129.97M | -56.3% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $134.93M | -12.4% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $134.66M | +11.3% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $84.85M | -17.1% |
Compare RYTM, MRVI, STOK, LFVN side by side · Screen every company in Pharmaceutical Preparations ↗